medical device investing AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study
pharmaceutical investing ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2